Literature DB >> 2274318

Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin.

M Takumida1, I Nishida, M Nikaido, K Hirakawa, Y Harada, D Bagger-Sjöbäck.   

Abstract

The effect of the dosing schedule on aminoglycoside ototoxicity was investigated in the guinea pig. The animals were given amikacin or isepamicin either by once-daily intramuscular injection of 200 mg/kg or by twice-daily injections of 100 mg/kg for 28 days. The once-daily treatment induced a lesser degree of ototoxicity than the twice-daily injections, which may indicate that the once-daily treatment therapy has a potential value in the clinical use of aminoglycoside antibiotics. Isepamicin sulfate is a new aminoglycoside antibiotic currently undergoing clinical investigation. This study revealed that isepamicin also has ototoxic properties as has been observed in all other aminoglycosides. The degree of ototoxicity, however, was markedly less than that of amikacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2274318     DOI: 10.1159/000276162

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  4 in total

Review 1.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

2.  Temporal variation in nephrotoxicity of low doses of isepamicin in rats.

Authors:  Y Yoshiyama; L Grenier; P Gourde; M Simard; L Lin; N J Morin; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Isepamicin disposition in subjects with various degrees of renal function.

Authors:  C E Halstenson; J S Kelloway; M B Affrime; C C Lin; M A Teal; B E Shapiro; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 4.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.